Neither an art nor a science, writing software is more akin to carpentry or watchmaking. We’re going to miss it.

Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...